The sponsor's number one sin is inadequate monitoring. That is a CRA story.

When the FDA inspects a sponsor or CRO rather than a site, one finding tops the list, and it should interest every CRA in the industry. The flagship sponsor citation is failure to adequately monitor the clinical trial. Read as a compliance matter, it is a regulatory problem. Read as a labor matter, it is a statement about how thinly monitoring is staffed, and that is the more interesting reading.

The number

In fiscal 2024, the FDA inspected roughly 125 sponsors, and about 31 of them, close to a quarter, drew a Form 483 listing inspection observations. The recurring sponsor findings were consistent: inadequate monitoring of clinical sites, monitoring plans that were not followed, late safety reporting, and inadequate validation. And here is the part worth sitting with: analysts who track these metrics note that the roughly one-in-four citation rate has not materially changed in about a decade. This is not a bad year. It is a structural, persistent gap in sponsor oversight.

Why "inadequate monitoring" is a headcount problem

Monitoring is what CRAs do. When the FDA cites a sponsor for inadequate monitoring or for not following its monitoring plan, it is saying, in regulatory language, that the trial was not watched closely enough. There are only a few ways that happens: too few monitors, monitors stretched across too many sites, visits spaced too far apart, or remote monitoring leaned on past the point where it catches what an on-site visit would. Every one of those is a resourcing decision. A persistent, decade-long pattern of inadequate-monitoring findings is, in effect, a persistent pattern of under-resourced monitoring.

That reframes the citation. It is not only evidence that some sponsors cut corners. It is evidence that the monitoring function is chronically run lean across the industry, to the point where the regulator keeps catching the shortfall.

What it means for CRAs

Two things follow, and they point in the same direction. First, when a sponsor gets cited for inadequate monitoring, the fix is more monitoring: more frequent visits, more source-data verification, for-cause visits, revised monitoring plans. That is directly more CRA hours, often across a whole program, not just the cited site. A warning letter for weak monitoring is a work-generating event for the monitoring workforce.

Second, and longer-term, the structural nature of the gap is a demand signal. If sponsors are persistently under-resourcing the function the FDA keeps flagging, then quality monitoring is chronically scarce relative to what compliance actually requires. Scarcity relative to need is leverage, and it argues that rigorous, inspection-ready CRAs are worth more than the lean staffing models assume.

What the data cannot tell you

The FDA metrics tell you sponsors are cited for inadequate monitoring at a steady rate. They cannot tell you what the CRA teams behind those trials were actually carrying: how many sites per monitor, how many concurrent studies, how much the monitoring budget was cut before the finding landed. That is the resourcing reality behind the citation, and it lives only with the CRAs who lived it. If you monitor trials, your site load and your workload are exactly the missing evidence. Add your datapoint, and put real numbers behind the FDA's most persistent sponsor finding.